Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 4, 2020

Primary Completion Date

March 29, 2022

Study Completion Date

May 9, 2022

Conditions
Invasive Fungal Infections
Interventions
DRUG

fosmanogepix

IV and oral fosmanogepix

Trial Locations (15)

1070

Cliniques Universitaires de Bruxelles Hôpital Erasme - Department of Infectious Diseases, Brussels

3000

UZ Leuven - Department of Haematology, Leuven

5530

CHU UCL Namur - Mont- Godinne University Hospital - Intensive Care Unit, Yvoir

27710

Duke Department of Pharmacy/Investigational Drug Service (IDS), Durham

Duke Medicine Pavilion, Durham

Duke University Medical Center (Duke South Clinic), Durham

Duke University Medical Center(Duke Hospital), Durham

55131

Universitätsmedizin der Johannes Gutenberg-Universität Mainz III, Mainz

81737

Klinikum Neuperlach, Klinik fur Hamatologie und Onkologie, München

91010

City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte

IP Address : City of Hope Investigational Drug Services (IDS), Duarte

3109601

Pharmacy, Haifa

Rambam Medical Center, Haifa

5262160

Pharmacy, Ramat Gan

Sheba Medical Center, Tel Hashomer, Ramat Gan

Sponsors
All Listed Sponsors
lead

Basilea Pharmaceutica

INDUSTRY